Explore (New York, N.Y.) · 2025
Clinical efficacy of Guishao Shengxue decoction in the treatment of pediatric immune thrombocytopenia: A randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Wei, Xie Xiaofei, Cui Shengtao, Xue Lin
Аннотация
BACKGROUND: Current treatments for pediatric immune thrombocytopenia (ITP) are effective but often associated with significant side effects, highlighting the need for safer and more sustainable alternatives. The objective of this study is to evaluate the clinical efficacy and safety of Guishao Shengxue Decoction (GSD) as a complementary therapy for ITP, aiming to provide a safer and more sustainable alternative to conventional treatments.
METHODS: In this randomized, double-blind study, 42 children with persistent or chronic ITP were enrolled and allocated equally to treatment or control groups. The treatment group received GSD combined with conventional therapy, while the control group received a placebo combined with conventional therapy for six months. Efficacy outcomes included platelet parameters, immune and hematological markers, and safety evaluations.
RESULTS: The treatment group demonstrated higher complete response (33.33% vs. 14.29%), overall response rate (95.24% vs. 71.43%), and durable response (95.24% vs. 80.95%) compared to the control group. Platelet indices and hematological parameters improved significantly in the treatment group, along with reduced platelet-associated immunoglobulins and better immune modulation.
CONCLUSIONS: GSD enhances clinical outcomes, supports platelet recovery, and modulates immune function in pediatric ITP, offering a safe and effective adjunct to conventional therapy.
METHODS: In this randomized, double-blind study, 42 children with persistent or chronic ITP were enrolled and allocated equally to treatment or control groups. The treatment group received GSD combined with conventional therapy, while the control group received a placebo combined with conventional therapy for six months. Efficacy outcomes included platelet parameters, immune and hematological markers, and safety evaluations.
RESULTS: The treatment group demonstrated higher complete response (33.33% vs. 14.29%), overall response rate (95.24% vs. 71.43%), and durable response (95.24% vs. 80.95%) compared to the control group. Platelet indices and hematological parameters improved significantly in the treatment group, along with reduced platelet-associated immunoglobulins and better immune modulation.
CONCLUSIONS: GSD enhances clinical outcomes, supports platelet recovery, and modulates immune function in pediatric ITP, offering a safe and effective adjunct to conventional therapy.